| scholarly article | Q13442814 |
| P356 | DOI | 10.4161/HV.25602 |
| P953 | full work available online at | http://www.tandfonline.com/doi/pdf/10.4161/hv.25602 |
| https://doi.org/10.4161/hv.25602 | ||
| https://europepmc.org/articles/PMC3981842 | ||
| https://europepmc.org/articles/PMC3981842?pdf=render | ||
| https://www.tandfonline.com/doi/pdf/10.4161/hv.25602?needAccess=true | ||
| P932 | PMC publication ID | 3981842 |
| P698 | PubMed publication ID | 23835446 |
| P5875 | ResearchGate publication ID | 247771570 |
| P50 | author | Tadeusz J Kochel | Q114336958 |
| Peifang Sun | Q117769706 | ||
| Kanakatte Raviprakash | Q117769707 | ||
| P2093 | author name string | Yossef Raviv | |
| Tadeusz Kochel | |||
| Thomas Luke | |||
| Nicholas Martin | |||
| P2860 | cites work | Dengue | Q24570132 |
| From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine | Q24737418 | ||
| Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes | Q27478075 | ||
| A Heterologous DNA Prime-Venezuelan Equine Encephalitis Virus Replicon Particle Boost Dengue Vaccine Regimen Affords Complete Protection from Virus Challenge in Cynomolgus Macaques | Q27484994 | ||
| A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus | Q27486406 | ||
| Immunogenicity of a Psoralen-Inactivated Dengue Virus Type 1 Vaccine Candidate in Mice | Q27490882 | ||
| Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | Q29616259 | ||
| Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever | Q29619530 | ||
| Dengue | Q29619772 | ||
| Evidence That Maternal Dengue Antibodies Are Important in the Development of Dengue Hemorrhagic Fever in Infants | Q29620637 | ||
| Review of accidents caused by incomplete inactivation of viruses | Q30421151 | ||
| Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope | Q33984221 | ||
| Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine | Q34206177 | ||
| Next-Generation Dengue Vaccines: Novel Strategies Currently Under Development | Q35491639 | ||
| Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity | Q36540164 | ||
| A dengue DNA vaccine formulated with Vaxfectin®is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits | Q36849774 | ||
| The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease | Q37903445 | ||
| Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults | Q39955421 | ||
| Photochemical Inactivation of DNA and RNA Viruses by Psoralen Derivatives | Q40171866 | ||
| Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. | Q40334688 | ||
| Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial | Q40342385 | ||
| Pressure-inactivated yellow fever 17DD virus: implications for vaccine development | Q40421425 | ||
| A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. | Q40475448 | ||
| An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model | Q40504189 | ||
| Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine | Q40536052 | ||
| Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques | Q40619965 | ||
| Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein | Q40624173 | ||
| Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys | Q40660960 | ||
| Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells | Q40661844 | ||
| Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness | Q40759851 | ||
| Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development | Q45370951 | ||
| Hepatitis and hepatitis A vaccine: a glimpse of history | Q47275466 | ||
| The reaction of formaldehyde with proteins; demonstration of intermolecular cross-linking by means of osmotic pressure measurements | Q47887080 | ||
| Photochemical Inactivation of Alpha‐ and Poxviruses | Q54350515 | ||
| Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation | Q68181949 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Dengue virus | Q476209 |
| P304 | page(s) | 2336-2341 | |
| P577 | publication date | 2013-07-08 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice | |
| Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4′-aminomethyl-trioxsalen) is highly immunogenic in mice | |||
| P478 | volume | 9 |
| Q39809317 | 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus |
| Q28584386 | Antiviral effect of compounds derived from the seeds of Mammea americana and Tabernaemontana cymosa on Dengue and Chikungunya virus infections |
| Q90405338 | Comparison of purified psoralen-inactivated and formalin-inactivated dengue vaccines in mice and nonhuman primates |
| Q35783544 | Immunogenic Properties of a BCG Adjuvanted Chitosan Nanoparticle-Based Dengue Vaccine in Human Dendritic Cells |
| Q90723502 | Inactivation of Zika Virus by Photoactive Iodonaphthyl Azide Preserves Immunogenic Potential of the Virus |
| Q28649479 | Inactivation of non-enveloped virus by 1,5 iodonaphthyl azide |
| Q38596321 | Next generation dengue vaccines: A review of the preclinical development pipeline |
| Q57492837 | Photochemical Treatment of APCs Can Eliminate Associated Viruses and Maintain the APC Function for Generating Antigen-Specific CTLs Ex Vivo |
| Q36333651 | Psoralen Inactivation of Viruses: A Process for the Safe Manipulation of Viral Antigen and Nucleic Acid |
Search more.